These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33034902)

  • 1. Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients.
    Cassin R; Visentin A; Giannarelli D; Noto A; Mauro FR; Baldini L; Trentin L; Reda G
    Hematol Oncol; 2021 Feb; 39(1):141-144. PubMed ID: 33034902
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
    Pleyer C; Tian X; Rampertaap S; Mu R; Soto S; Superata J; Gaglione E; Sun C; Lotter J; Stetler-Stevenson M; Yuan CM; Maric I; Pittaluga S; Rosenzweig S; Fleisher T; Wiestner A; Ahn IE
    Am J Hematol; 2020 Nov; 95(11):E310-E313. PubMed ID: 32808680
    [No Abstract]   [Full Text] [Related]  

  • 3. A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
    Cheson BD
    Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):3-7. PubMed ID: 33843868
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
    Molica S; Baumann T; Giannarelli D
    Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
    [No Abstract]   [Full Text] [Related]  

  • 5. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Greil R; Tedeschi A; Moreno C; Anz B; Larratt L; Simkovic M; Gill D; Gribben JG; Flinn IW; Wang Z; Cheung LWK; Nguyen AN; Zhou C; Styles L; Demirkan F
    Ann Hematol; 2021 Jul; 100(7):1733-1742. PubMed ID: 34018029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 7. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
    Visentin A; Mauro FR; Cibien F; Vitale C; Reda G; Fresa A; Ciolli S; Pietrasanta D; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Scarfò L; Sportoletti P; Pravato S; Piazza F; Coscia M; Laurenti L; Molica S; Foà R; Cuneo A; Trentin L
    Am J Hematol; 2022 Mar; 97(3):E95-E99. PubMed ID: 34904743
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Baumann T; Montserrat E
    Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
    [No Abstract]   [Full Text] [Related]  

  • 9. Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Barnea Slonim L; Ma S; Behdad A; Chen Q
    Br J Haematol; 2020 Oct; 191(1):e22-e25. PubMed ID: 32677079
    [No Abstract]   [Full Text] [Related]  

  • 10. An oral drug for chronic lymphocytic leukemia.
    Koehler A
    JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.
    Ishdorj G; Streu E; Lambert P; Dhaliwal HS; Mahmud SM; Gibson SB; Banerji V; Marshall AJ; Johnston JB
    Blood Adv; 2019 Jul; 3(14):2188-2198. PubMed ID: 31324639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral aspergillosis in a patient on ibrutinib therapy.
    Creuzet E; Nourrisson C; Chaleteix C; Poirier P; Moniot M
    Br J Haematol; 2021 Jun; 193(6):1025. PubMed ID: 33748950
    [No Abstract]   [Full Text] [Related]  

  • 13. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
    Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M
    Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma.
    Shulman K; Kazarin O; Tannous E; Sofer O
    Isr Med Assoc J; 2021 Jun; 23(6):385-386. PubMed ID: 34155856
    [No Abstract]   [Full Text] [Related]  

  • 15. Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
    Miller CR; Huang Y; Ruppert AS; Labanowska J; Jaglowski SM; Maddocks KJ; Rogers KA; Bhat S; Kittai AS; Grever M; Lapalombella R; Abruzzo LV; Heerema NA; Byrd JC; Hertlein EK; Woyach JA
    Leukemia; 2021 Nov; 35(11):3287-3290. PubMed ID: 33820961
    [No Abstract]   [Full Text] [Related]  

  • 16. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Sun C; Tian X; Lee YS; Gunti S; Lipsky A; Herman SE; Salem D; Stetler-Stevenson M; Yuan C; Kardava L; Moir S; Maric I; Valdez J; Soto S; Marti GE; Farooqui MZ; Notkins AL; Wiestner A; Aue G
    Blood; 2015 Nov; 126(19):2213-9. PubMed ID: 26337493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
    Ysebaert L; Quinquenel A; Bijou F; Ferrant E; Michallet AS;
    Eur J Cancer; 2020 Aug; 135():170-172. PubMed ID: 32585590
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aspergillus spondylodiscitis in a patient treated with ibrutinib].
    Petitdemange A; Martin A; Ruch Y; Chatron E; Karol A; Hansmann Y
    Med Mal Infect; 2020 May; 50(3):296-297. PubMed ID: 31722863
    [No Abstract]   [Full Text] [Related]  

  • 19. [Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
    Kumekawa H; Watanabe D; Tamura K; Mizuchi D
    Rinsho Ketsueki; 2022; 63(1):62-65. PubMed ID: 35135954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Ishdorj G; Nugent Z; Squires M; Kost S; Banerji V; Davidson L; Katyal CS; Marshall A; Gibson SB; Johnston JB
    Leuk Res; 2021 Oct; 109():106628. PubMed ID: 34134067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.